This US Generics Stock Rises 53% in 1 Year: What Is Powering the Rally?
- September 10, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Aurobindo Pharma CMP Rs 1,668.40 (10 Sep 2026). 1-year return 53.46%. 52W range Rs 1,036 to Rs 1,717. Market cap Rs 97,239 Cr. Q1 FY27 PAT Rs 1,032 Cr, up 25%.
Quick Answer
Aurobindo Pharma is the US generics stock behind a 1-year return of approximately 53%, rising from a 52-week low of Rs 1,036 to a record Rs 1,717. The rally was driven by 25% profit growth in Q1 FY27, an Rs 800 crore buyback, the Lannett acquisition and the launch of generic Advair in America. The stock trades at a PE near 26, below the industry average, but already sits above some brokerage targets.
This US generics stock has turned Rs 1 lakh into roughly Rs 1.53 lakh in twelve months. A Hyderabad-based drugmaker that earns the biggest slice of its sales in America delivered a 1-year return of 53.46% as of 10 September 2026, ranking 28th in a screen of 101 large-cap and mid-cap NSE shares.
The company is Aurobindo Pharma Ltd (NSE: AUROPHARMA), one of the largest Indian exporters of generic medicines to the United States. The Aurobindo Pharma share climbed from a 52-week low of Rs 1,036 to a record high of Rs 1,717, while the Nifty Pharma index fell over the same year. That gap is what makes this US generics stock stand out.
Click Here – Get Free Investment Predictions
How Much Has This US Generics Stock Returned in 1 Year?
This US generics stock has returned approximately 53.46% in one year, rising from around Rs 1,087 in September 2025 to Rs 1,668.40 at the close on 10 September 2026. The Aurobindo Pharma share price slipped 1.80% on the day from a previous close of Rs 1,698.90, but it still trades within about 3% of its 52-week high.
Here is how the US generics stock has performed across time frames in the 101-stock screen:
| Period | Return (%) | Rank (out of 101) |
|---|---|---|
| 1 Month | 0.60% | 89 |
| 6 Months | 25.21% | 55 |
| 1 Year | 53.46% | 28 |
| 3 Years | 81.90% | 52 |
| 5 Years | 131.06% | 49 |
Returns are simple price changes and are not annualised. The 1-month figure of 0.60% shows the rally has paused after a strong run from April to August. No stock split or bonus issue took place in the past year, so the 53% gain reflects real price appreciation.
The bigger story is relative strength. Over the same 12 months, the Nifty 50 fell nearly 5% and the Nifty Pharma index dropped more than 20%, according to market data from early September. This US generics stock went the other way.
Why Did This US Generics Stock Rise 53% in a Year?
This US generics stock rose 53% because four things came together: steady earnings growth, a Rs 800 crore buyback, the closing of the Lannett acquisition and the start of complex product launches in America, backed by fast growth outside the US. Each one gave investors a fresh reason to re-rate Aurobindo Pharma.
1. Steady Profit Growth in Every Quarter
Aurobindo Pharma reported Q1 FY27 revenue from operations of Rs 9,150 crore, up about 16.3% year on year. EBITDA rose 17.3% to Rs 1,881 crore and net profit jumped 25.2% to Rs 1,032 crore, crossing the Rs 1,000 crore mark.
Gross margin improved by around 153 basis points to 60.4%. For a US generics stock, where price erosion is a constant threat, rising gross margins suggest a better product mix rather than just higher volume.
2. Rs 800 Crore Share Buyback in April 2026
In April 2026 the board approved a share buyback worth Rs 800 crore at Rs 1,475 per share. The Aurobindo Pharma share price jumped around 4% to a then 52-week high of Rs 1,355.50 on the day the buyback meeting was announced.
The buyback price was well above where the stock traded at the time. That signalled management confidence and put a visible floor under the US generics stock during a weak broader market.
3. Lannett Acquisition Adds US Manufacturing
Aurobindo Pharma closed its acquisition of Lannett, a US generics maker, for a consideration of about USD 247 million. Lannett runs at only around 40% capacity utilisation, and management has laid out a 12-month plan to improve procurement and plant efficiency.
A domestic brokerage estimates Lannett could eventually reach USD 500 million in revenue. Local manufacturing also reduces the tariff and supply-chain risk that hangs over every Indian US generics stock.
4. Generic Advair Marks Entry Into US Inhalation
On 31 August 2026, Lannett launched a generic version of Advair Diskus in the 100/50 mcg and 250/50 mcg strengths for asthma and COPD. It is the first product from the company’s inhalation pipeline to reach the US market.
Inhalers are hard to copy, so competition is thinner and prices hold better than in plain tablets. This launch is a key step in moving the US generics stock away from commoditised oral solids towards complex generics.
5. Europe, Growth Markets and Pen-G Add Diversification
Europe formulations revenue grew 25.6% to Rs 2,937 crore in Q1 FY27, and growth markets such as Canada, Indonesia and China rose 37.7% to Rs 1,063 crore. The Pen-G plant, backed by PLI incentives, is expected to add around Rs 700 crore of revenue as utilisation climbs to 60% to 80%.
These businesses mean this US generics stock is no longer a pure bet on American drug pricing, even though the US remains its largest market.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
US Generics Stock Financials: Quarterly Trend
The quarterly numbers show a clean upward line. Total income rose in each of the last five quarters and net profit grew from Rs 824 crore to Rs 1,032 crore, which gives this US generics stock earnings support for its re-rating.
| Quarter | Total Income (Rs Cr) | Net Profit (Rs Cr) | Net Margin | EPS (Rs) |
|---|---|---|---|---|
| Jun 2025 | 7,973 | 824 | 10.58% | 14.20 |
| Sep 2025 | 8,406 | 848 | 10.30% | 14.61 |
| Dec 2025 | 8,834 | 910 | 11.10% | 15.67 |
| Mar 2026 | 8,970 | 921 | 10.53% | 15.86 |
| Jun 2026 | 9,415 | 1,032 | 11.60% | 17.86 |
For the full year FY26, revenue rose to about Rs 34,145 crore from Rs 32,346 crore, while net profit was nearly flat at Rs 3,503 crore. Operating cash flow improved sharply to Rs 5,526 crore from Rs 3,925 crore, and debt to equity remains low at about 0.21.
US formulations revenue in Q1 FY27 stood at Rs 3,770 crore, or about USD 399 million, up 8.1% year on year on the back of volume gains and 10 new launches. That is slower than Europe, but it is still the core engine of the US generics stock.
Is the US Generics Stock Still Reasonably Valued?
Yes, on trailing earnings the US generics stock looks moderately valued. Aurobindo Pharma trades at a PE of approximately 26.2 against an industry PE of about 38.3, with a price to book of 2.57 and a market cap of around Rs 97,239 crore.
| Metric | Aurobindo Pharma | Comment |
|---|---|---|
| Share Price (10 Sep 2026) | Rs 1,668.40 | Down 1.80% on the day |
| 52-Week High / Low | Rs 1,717 / Rs 1,036 | About 3% below high |
| PE Ratio (TTM) | 26.21 | Industry PE 38.26 |
| Price to Book | 2.57 | Book value Rs 658.53 |
| ROE | 9.25% | Modest for the sector |
| Debt to Equity | 0.21 | Low debt |
| Promoter Holding (Jun 2026) | 51.88% | Stable |
The discount to peers partly reflects a modest ROE of 9.25% and a history of US regulatory issues. Investors re-rating this US generics stock are betting that returns improve as new plants and acquisitions ramp up.
Who Is Buying This US Generics Stock?
Foreign institutional investors have been adding. FII holding in Aurobindo Pharma rose from 13.94% in December 2025 to 16.38% in June 2026, while domestic institutions trimmed from 27.68% to 25.10%.
| Shareholder | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | 51.88% |
| FIIs | 14.37% | 13.94% | 15.24% | 16.38% |
| DIIs | 26.93% | 27.68% | 25.87% | 25.10% |
| Public | 6.88% | 6.55% | 7.08% | 6.64% |
Promoter holding has been rock steady at about 51.9%. Large domestic funds, including a pension fund and the country’s biggest insurer, hold meaningful stakes in the US generics stock, and retail ownership is small at under 7%.
Key Risks for This US Generics Stock
The main risk for this US generics stock is regulation. Recent inspections led to two observations at one subsidiary and five at the Eugia injectables unit, and any warning letter could delay approvals and hurt US sales.
Price erosion: US formulations grew only 8.1% in Q1 FY27, far slower than Europe. Generic prices in America fall steadily, so the US generics stock needs a constant stream of new launches to stand still.
Integration risk: Lannett runs at around 40% utilisation. If the turnaround takes longer than 12 months, the acquisition could drag on margins instead of lifting them.
Tariff and policy risk: Trade policy changes in the US could raise costs for any Indian US generics stock. Local manufacturing helps, but most products are still made in India.
Stretched near-term momentum: The share gained just 0.60% in the last month and trades above several brokerage targets. After a 53% run, this US generics stock could consolidate or correct if the next quarter disappoints.
Download the Univest iOS App or Univest Android App to track the Aurobindo Pharma share price live
Aurobindo Pharma Share: Analyst View
The analyst view on the Aurobindo Pharma share is broadly positive but more cautious after the rally. In June 2026, a domestic brokerage kept a buy rating on the US generics stock, saying more than half of the investments made over the past five years were now ready to deliver, and projected revenue and profit CAGR of 15% and 24% through FY28.
After the Q1 FY27 results, another domestic brokerage cut its rating to hold because the stock had run ahead of its estimates. Analysts tracking the US generics stock now watch three things: the generic Advair ramp-up, Lannett’s utilisation and any change in US regulatory status.
Aurobindo Pharma Share Price Target
The highest recent Aurobindo Pharma share price target from a domestic brokerage is Rs 1,753, raised from Rs 1,680 in June 2026. Against the Aurobindo Pharma share price of Rs 1,668.40, that implies potential upside of roughly 5%.
| Parameter | Figure |
|---|---|
| Aurobindo Pharma Share Price (10 Sep 2026) | Rs 1,668.40 |
| Domestic Brokerage Target (Buy, Jun 2026) | Rs 1,753 |
| Domestic Brokerage Target (Add, Jun 2026) | Rs 1,630 |
| Domestic Brokerage Target (Hold, Aug 2026) | Rs 1,600 |
| Buyback Price (Apr 2026) | Rs 1,475 |
| 52-Week Low | Rs 1,036 |
Two other domestic brokerages have an Aurobindo Pharma share price target of Rs 1,630 and Rs 1,600, both below the current Aurobindo Pharma share price. That spread tells you the market has already priced in much of the near-term good news, and targets are estimates, not certainties.
Conclusion
Aurobindo Pharma earned its 53% gain through steady profit growth, a confidence-boosting buyback and a clear push into complex products through Lannett and generic Advair. It did this while the broader pharma index fell, which makes it one of the stronger US generics stock stories of the year.
The Aurobindo Pharma share price now sits close to its record high and above some brokerage targets. Existing holders of this US generics stock can track Advair uptake, Lannett margins and FDA inspection outcomes, while new investors may prefer staggered buying rather than chasing the stock near its peak.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which US generics stock rose 53% in 1 year?
Ans. Aurobindo Pharma (NSE: AUROPHARMA) is the US generics stock that gained approximately 53.46% in one year as of 10 September 2026. It ranked 28th among 101 large-cap and mid-cap NSE stocks on 1-year return.
Why did the Aurobindo Pharma share price rise?
Ans. The rally came from steady quarterly profit growth, a Rs 800 crore buyback at Rs 1,475 per share, the Lannett acquisition and the launch of generic Advair in the US. Strong Europe and growth market sales added further support.
What were Aurobindo Pharma Q1 FY27 results?
Ans. Revenue from operations rose about 16.3% to Rs 9,150 crore and net profit grew 25.2% to Rs 1,032 crore. EBITDA increased 17.3% to Rs 1,881 crore and gross margin improved to 60.4%, extending the earnings run of the US generics stock.
What is the Aurobindo Pharma share price target?
Ans. The highest recent target from a domestic brokerage is Rs 1,753, implying about 5% upside from Rs 1,668.40. Two other domestic brokerages have targets of Rs 1,630 and Rs 1,600, which are below the current price.
What is the 52-week high and low of Aurobindo Pharma?
Ans. The 52-week high is Rs 1,717 and the 52-week low is Rs 1,036 on NSE. The stock closed at Rs 1,668.40 on 10 September 2026, about 3% below its high, keeping the US generics stock near record territory.
Is this US generics stock overvalued?
Ans. Not on trailing numbers. The PE of about 26.2 is below the industry PE of around 38.3, although ROE is modest at 9.25% and the price is near a record high.
What is Lannett and why does it matter to Aurobindo Pharma?
Ans. Lannett is a US generics maker that Aurobindo Pharma acquired for about USD 247 million. It adds US manufacturing capacity and launched generic Advair, the company’s first US inhalation product, on 31 August 2026.
Should I invest in a US generics stock after a 53% rally?
Ans. Much of the good news is already in the price, and some brokerage targets sit below the current level. Staggered buying, attention to FDA inspection outcomes and advice from a SEBI-registered advisor are sensible steps.
